好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Post-COVID Conditions in People with Multiple Sclerosis: A Cross-sectional Multicenter Study
Multiple Sclerosis
P1 - Poster Session 1 (8:00 AM-9:00 AM)
6-002
We compared the characteristics, risk factors, and outcomes of post-COVID conditions (PCC) in people with multiple sclerosis (pwMS) with healthy controls and identified relevant risk factors and associated neurological outcomes in pwMS.
PCC (or long-COVID) is a major public health concern. Diagnosis and management of PCC in pwMS are challenging because both conditions have similar symptoms, including fatigue, cognitive impairment, weakness, and paresthesia.
In this cross-sectional, multi-center study, participants completed a one-time web-based survey (Aug-Dec 2022) ascertaining demographics, infections, vaccination status, neurological disease state, post-COVID symptoms (PCS), and MS outcomes. We separately evaluated new and worsening PCS that started 1 month after the initial onset of acute COVID-19 by comparing them to pre-COVID-19 baseline symptoms. We defined PCC as having ≥1 PCS. Descriptive statistics, multivariable regression, and mediation analyses were performed.
969 pwMS and 1003 controls completed the surveys. 613 pwMS (63.5%) and 614 controls (61.2%) experienced a confirmed or suspected SARS-CoV-2 infection. PwMS had higher odds of developing any new PCS (OR=1.55; 95%CI=1.22-1.98; p=0.0003) and any worsening PCS (OR=3.39; 95%CI=2.64-4.36; p<0.0001). PwMS were more likely to develop new pulmonary and HENT symptoms and worsening systemic, musculoskeletal, and neuropsychiatric symptoms. The development of either new (beta=1.9; 95%CI=0.9-2.9) or worsening (beta=2.9; 95%CI=2.0-3.9) PCS was associated with subsequently worse MS disability (based on the multiple sclerosis rating scale-revised). Among pwMS, women had greater risk for PCC than men. Acute COVID-19 severity mediated 70% of the association between MS diagnosis and PCC.
Compared to controls, pwMS experienced an increased risk of developing both new and worsening PCS. Careful clinical evaluation to distinguish new versus worsening symptoms in pwMS following acute COVID-19 is crucial. Having PCC in pwMS was associated with greater MS disability, highlighting the importance of recognizing and effectively managing PCC in this vulnerable population.
Authors/Disclosures
Jiyeon Son, MD
PRESENTER 		Ms. Son has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen .
Chen Hu (University of Pittsburgh) Chen Hu has nothing to disclose.
Lindsay S. McAlpine, MD (Yale University) Dr. McAlpine has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Law Firm. The institution of Dr. McAlpine has received research support from NIH.
Amit Bar-Or, MD, FRCPC (University of Pennsylvania) Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Genentech. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merk/EMD Serono. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for cabaletta. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck/EMD Serono. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. The institution of Dr. Bar-Or has received research support from Novartis. The institution of Dr. Bar-Or has received research support from Biogen. The institution of Dr. Bar-Or has received research support from Roche/Genentech.
Megan Dahl No disclosure on file
Sugeidy Ferreira Brito (Columbia University Medical Center) No disclosure on file
Katelyn S. Kavak (Jacobs MS Treatment and Research Center) Ms. Kavak has nothing to disclose.
Kaho Onomichi Kaho Onomichi has nothing to disclose.
Christopher Perrone, MD (University of Pennsylvania, Department of Neurology) Dr. Perrone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono.
Claire Riley, MD, FAAN Dr. Riley has received personal compensation for serving as an employee of AstraZeneca. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cabaletta Bio. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics.
Emily Song (University of Pittsburgh) Emily Song has nothing to disclose.
Elizabeth Walker No disclosure on file
Bianca Weinstock-Guttman, MD (Department of Neurology, University At Buffalo) Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH.
Philip De Jager, MD, PhD (Columbia University Irving Medical Center) Dr. De Jager has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Puretech. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for roche. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. The institution of Dr. De Jager has received research support from roche. The institution of Dr. De Jager has received research support from puretech.
Erin Longbrake, MD, PhD, FAAN (Yale University) Dr. Longbrake has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Longbrake has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Longbrake has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Longbrake has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Longbrake has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Longbrake has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Longbrake has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Longbrake has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Longbrake has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for ACTRIMS. Dr. Longbrake has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology. The institution of Dr. Longbrake has received research support from Genentech. The institution of Dr. Longbrake has received research support from NINDS K23. The institution of Dr. Longbrake has received research support from Robert Patterson Leet Trust. The institution of Dr. Longbrake has received research support from Biogen. The institution of Dr. Longbrake has received research support from National MS Society. The institution of Dr. Longbrake has received research support from Department of Defense. Dr. Longbrake has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with Department of Defense (CDMRP). Dr. Longbrake has received personal compensation in the range of $500-$4,999 for serving as a Programmatic Review with Department of Defense (CDMRP). Dr. Longbrake has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with National Institute of Health .
Zongqi Xia, MD, PhD The institution of Dr. Xia has received research support from National Institute of Health. The institution of Dr. Xia has received research support from Genentech/Roche.